<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01594099</url>
  </required_header>
  <id_info>
    <org_study_id>GCR-02</org_study_id>
    <nct_id>NCT01594099</nct_id>
  </id_info>
  <brief_title>Concurrent Chemoradiotherapy for Cervical Cancer in Elderly Women</brief_title>
  <official_title>Weekly Cisplatin or Weekly Liposome Paclitaxel Concurrent Radiation Therapy in Treating Elderly People With Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Health Science Center of Xi’an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Health Science Center of Xi’an Jiaotong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficiency and safety of weekly Cisplatin
      /Liposome paclitaxel concurrent chemoradiothrapy in the treatment of locally advanced
      cervical cancer in elderly women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Concurrent radiotherapy is the standard treatment of inoperable cervical cancer .Due to the
      physical conditions, elderly patients usually associated with medical complications, so
      generally just receive radiotherapy alone. Recently, some retrospective studies have shown
      that the impact of chemotherapy did not cause an increase in the complication rate among
      elderly patients as compared to younger patients with cervical cancer, and may improve the
      survival when concurrent with radiotherapy. Cisplatin and paclitaxel are two effective drug
      in treating cervical cancer, but whether they are safe enough for elderly when concurrent
      with radiotherapy, there are no clearly reports. In this study ,we replace the conventional
      dose chemotherapy with weekly cisplatin or lipsome paclitaxel , to compare the efficiency and
      safety of weekly cisplatin / liposome paclitaxel concurrent chemoradiotherapy and
      radiotherapy alone in the treatment of cervical cancer in elderly patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>1 month after the treatment completed</time_frame>
    <description>Objective Response Rate: Complete response (CR)+ Partial response (PR) rates base on RECIST evaluation system.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Participants will be followed from the treatment begin to 1 month after the treatment end.</time_frame>
    <description>Record the Number of participants with adverse events and the Grades of the AE according to CTCAE v3.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local Control Rate</measure>
    <time_frame>Participants will be followed every year for the duration of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Free Survival Rate</measure>
    <time_frame>From date of randomization until tumor recurrence or metastasis,assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>From date of randomization until the date of death from any cause,assessed up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy plus cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy plus liposome paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>irradiation</intervention_name>
    <description>EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.
Brachytherapy :Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).</description>
    <arm_group_label>Radiotherapy alone</arm_group_label>
    <other_name>RT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.
Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).
Chemotherapy: Cisplatin (20mg /week) will be carry out in the 2nd to 6th week during radiation therapy.</description>
    <arm_group_label>Radiotherapy plus cisplatin</arm_group_label>
    <other_name>RT+C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposome paclitaxel</intervention_name>
    <description>EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.
Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).
Chemotherapy: Liposome paclitaxel (40mg /m2/2weeks) will be carry out in the 2nd ,4th,6th week during radiation therapy.</description>
    <arm_group_label>Radiotherapy plus liposome paclitaxel</arm_group_label>
    <other_name>RT+Lp</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proven squamous carcinoma of cervix

          2. FIGO stageⅡB and ⅢB

          3. Over 65 years

          4. Do not receive other treatment

          5. Performance index ECOG grade 0 to 2

          6. Normal ECG

          7. Normal hematological parameters

          8. Normal renal and liver function tests

        Exclusion Criteria:

          1. Concomitant disease which may adversely affect the outcome

          2. Poor nutritional status

          3. Medical or psychological condition precluding treatment

          4. Previous treatment

          5. Concurrent treatment for any cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen M W, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Affiliated Hospital of Medical College of Xi'an Jiaotong University</affiliation>
  </overall_official>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2012</study_first_submitted>
  <study_first_submitted_qc>May 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2012</study_first_posted>
  <last_update_submitted>May 6, 2012</last_update_submitted>
  <last_update_submitted_qc>May 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Health Science Center of Xi’an Jiaotong University</investigator_affiliation>
    <investigator_full_name>Liu Zi</investigator_full_name>
    <investigator_title>Profesor</investigator_title>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <keyword>elderly women</keyword>
  <keyword>concurrent chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

